NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS NASDAQ) stock market data APIs
$18.2764
-0.41(-2.2%)
as of June 23, 2025
Try our APIs with
free plan!
NewAmsterdam Pharma Company N.V. Ordinary Shares Financial Data Overview
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Prev. Close
18.2764
Open
17.8615
High
18.5442
Low
17.5338
52 wk Range
14.06-27.29
Market Cap
2 044 M
Shares Outstanding
112 M
Revenue
47 140 K
EPS
-0.3016
Beta
-0.025
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NewAmsterdam Pharma Company N.V. Ordinary Shares data using free add-ons & libraries
Get NewAmsterdam Pharma Company N.V. Ordinary Shares Fundamental Data
NewAmsterdam Pharma Company N.V. Ordinary Shares Fundamental data includes:
- Net Revenue: 47 140 K
- EBITDA: -189 582 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get NewAmsterdam Pharma Company N.V. Ordinary Shares Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -0.4364
Get NewAmsterdam Pharma Company N.V. Ordinary Shares End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NewAmsterdam Pharma Company N.V. Ordinary Shares News
New
Citi initiates coverage on biotech amid improving sentiment in sector
Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor ...
Citi initiates coverage on biotech amid improving sentiment in sector
Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor...
NewAmsterdam Pharma's SWOT analysis: stock poised for cardiovascular breakthrough
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is making waves in the cardiovascular drug market with its lead asset, obicetrapib, a cholesteryl ester transfer protein (CETP) inhibitor. As the company...
NewAmsterdam Pharma Company N.V. (NAMS) Initiated with a Buy at Stifel
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is one of the 13 Biotech Stocks with Huge Upside Potential. It is now under Stifel’s coverage, with a buy rating and a $44 price target.NewAmsterdam Ph...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
